Vanguard Group Inc Pharma Cyte Biotech, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 192,387 shares of PMCB stock, worth $357,839. This represents 0.0% of its overall portfolio holdings.
Number of Shares
192,387
Previous 174,602
10.19%
Holding current value
$357,839
Previous $413,000
8.72%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PMCB
# of Institutions
31Shares Held
1.12MCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6328KShares$609,1550.33% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$328,4850.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$171,2817.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$153,8720.18% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA54.8KShares$101,9910.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $38.6M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...